Womenra: Restore Female Sexual Desire and Satisfaction
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.02 | $50.20 (0%) | 🛒 Add to cart |
| 20 | $3.01 | $100.41 $60.24 (40%) | 🛒 Add to cart |
| 30 | $2.34 | $150.61 $70.28 (53%) | 🛒 Add to cart |
| 60 | $1.51 | $301.22 $90.37 (70%) | 🛒 Add to cart |
| 90 | $1.23 | $451.83 $110.45 (76%) | 🛒 Add to cart |
| 120 | $1.17 | $602.44 $140.57 (77%) | 🛒 Add to cart |
| 180 | $1.00 | $903.66 $180.73 (80%) | 🛒 Add to cart |
| 270 | $0.89 | $1355.49 $240.98 (82%) | 🛒 Add to cart |
| 360 | $0.84
Best per pill | $1807.32 $301.22 (83%) | 🛒 Add to cart |
Womenra is a clinically developed prescription medication designed to address hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by modulating neurotransmitters in the brain to help restore natural sexual motivation and reduce distress associated with low libido. This non-hormonal treatment offers a targeted approach for women seeking to regain a fulfilling intimate life without affecting systemic hormone levels.
Features
- Active ingredient: Flibanserin 100mg
- Non-hormonal mechanism of action
- Central nervous system targeting
- Once-daily bedtime administration
- FDA-approved for premenopausal women
- Requires prescription and medical supervision
Benefits
- Increases spontaneous sexual desire and reduces associated distress
- Improves satisfying sexual events frequency
- Enhances overall sexual satisfaction
- Non-hormonal approach minimizes systemic side effects
- Helps restore natural sexual response patterns
- May improve intimacy and relationship quality
Common use
Womenra is specifically indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by persistent deficiency or absence of sexual fantasies and desire for sexual activity, causing marked distress or interpersonal difficulty. The condition must not be better explained by another medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance. Clinical studies have demonstrated efficacy in women who experience distress due to low sexual desire that cannot be attributed to underlying medical or psychiatric conditions.
Dosage and direction
The recommended dosage is 100mg taken orally once daily at bedtime. Administration at bedtime is crucial due to the potential for dizziness, sleepiness, and fatigue. The tablet should be swallowed whole with water and not crushed or divided. Patients should avoid consuming alcohol during treatment with Womenra, as concomitant use increases the risk of severe hypotension and syncope. Treatment efficacy should be evaluated after 8 weeks of continuous therapy. If no meaningful improvement is observed after 8 weeks, discontinuation should be considered. Dosage adjustment is not recommended for patients with mild hepatic impairment, but Womenra is contraindicated in patients with moderate or severe hepatic impairment.
Precautions
Patients should be advised about the potential for hypotension and syncope, particularly during the initial titration period. Blood pressure should be monitored, especially in patients taking antihypertensive medications. Womenra may cause central nervous system depression, including somnolence and fatigue; patients should exercise caution when engaging in activities requiring complete mental alertness, such as driving or operating machinery, until they know how Womenra affects them. The risk of hypotension and syncope is increased with concomitant use of alcohol, strong CYP3A4 inhibitors, or other central nervous system depressants. Patients should be screened for hepatic impairment before initiation and periodically during treatment. Womenra may cause fetal harm if administered during pregnancy; effective contraception is recommended for women of reproductive potential.
Contraindications
Womenra is contraindicated in patients with known hypersensitivity to flibanserin or any component of the formulation. Concomitant use with strong or moderate CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, and several HIV medications, is contraindicated. Patients with hepatic impairment classified as Child-Pugh B or C should not use Womenra. The medication is contraindicated in patients who consume alcohol, either currently or with a history of alcohol use disorder. Concomitant use with other central nervous system depressants is contraindicated unless the benefit outweighs the risk and close monitoring is implemented.
Possible side effects
The most common adverse reactions (≥2% incidence) include dizziness (11.4%), somnolence (11.2%), nausea (10.4%), fatigue (9.2%), insomnia (4.9%), and dry mouth (2.4%). Syncope occurred in 0.4% of patients in clinical trials, with most cases occurring during the first 14 days of treatment. Hypotension was reported in 0.2% of patients. Less common side effects include anxiety, palpitations, and abdominal pain. The incidence of most adverse reactions decreases after the first month of treatment. Patients should be monitored for signs of hypotension, especially during initial treatment and after dosage increases.
Drug interaction
Womenra is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Concomitant use with strong CYP3A4 inhibitors increases flibanserin exposure approximately 7-fold and is contraindicated. Moderate CYP3A4 inhibitors may increase flibanserin exposure by approximately 4-fold and should be avoided. Concomitant use with alcohol significantly increases the risk of hypotension and syncope and is contraindicated. Womenra may potentiate the effects of CNS depressants, including benzodiazepines, opioids, and sedating antihistamines. The medication may interact with oral contraceptives, though no clinically significant interactions have been observed. Concomitant use with medications that affect blood pressure may increase the risk of hypotension.
Missed dose
If a dose is missed, patients should skip the missed dose and take the next dose at the regular time the following evening. Patients should not take two doses of Womenra within the same day, as this may increase the risk of adverse effects, particularly hypotension and syncope. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming treatment. Consistency in bedtime administration is important for maintaining therapeutic effects while minimizing side effects.
Overdose
In case of suspected overdose, immediate medical attention should be sought. Symptoms of overdose may include severe hypotension, syncope, and excessive sedation. There is no specific antidote for Womenra overdose. Treatment should consist of supportive measures, including continuous blood pressure monitoring and appropriate management of hypotension. Activated charcoal may be considered if administered within one hour of ingestion. Hemodialysis is unlikely to be effective due to Womenra’s high protein binding and extensive metabolism. Patients should be monitored for at least 24 hours due to the medication’s half-life of approximately 11 hours.
Storage
Store Womenra tablets at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the medication in its original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use Womenra beyond the expiration date printed on the packaging. Properly dispose of any unused or expired medication through medication take-back programs or according to FDA-recommended disposal methods.
Disclaimer
Womenra is a prescription medication that should be used only under the supervision of a qualified healthcare provider. This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Individual results may vary, and not all patients will experience the described benefits. Patients should discuss their medical history, current medications, and treatment goals with their healthcare provider before starting Womenra. The safety and efficacy of Womenra have not been established in postmenopausal women or men.
Reviews
Clinical trials demonstrate that 46-60% of women treated with Womenra experience meaningful improvement in sexual desire and distress scores compared to 29-38% with placebo. Patients report increased spontaneous sexual thoughts and improved relationship satisfaction. Many women note the most significant benefits after 4-8 weeks of consistent use. Some patients report that side effects diminish after the initial treatment period. Healthcare providers emphasize the importance of proper patient selection and adherence to administration guidelines for optimal outcomes. Real-world evidence supports the clinical trial data, with many patients experiencing improved quality of life and reduced distress related to sexual dysfunction.